Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

ROCKET AF Steering Committee & Investigators

doi:10.1161/JAHA.115.002197)

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

ROCKET AF Steering Committee & Investigators

Applied Medicine

Research output: Contribution to journal › Article › peer-review

12 Downloads (Pure)

Original language	English
Article number	e002197
Journal	JAMA
Volume	5
Issue number	3
DOIs	https://doi.org/10.1161/JAHA.115.002197)
Publication status	Published - 2016

Bibliographical note

The ROCKET AF trial was sponsored by Johnson & Johnson Pharmaceutical Research & Development (Raritan, NJ) and Bayer HealthCare AG (Leverkusen, Germany).

Keywords

atrial fibrillation
mortality
rivaroxaban
stroke
warfarin

Access to Document

10.1161/JAHA.115.002197)Licence: CC BY-NC

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation
Copyright 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. https://creativecommons.org/licenses/by-nc/4.0/
Final published version, 1.17 MBLicence: CC BY-NC

Cite this

@article{7e8813b0d1a64d6da398f5fc76828743,

title = "Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF",

keywords = "atrial fibrillation, mortality, rivaroxaban, stroke, warfarin",

author = "Mary Macleod and \{ROCKET AF Steering Committee \& Investigators\}",

note = "The ROCKET AF trial was sponsored by Johnson \& Johnson Pharmaceutical Research \& Development (Raritan, NJ) and Bayer HealthCare AG (Leverkusen, Germany). ",

year = "2016",

doi = "10.1161/JAHA.115.002197)",

language = "English",

volume = "5",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation

T2 - Data From ROCKET AF

AU - Macleod, Mary

AU - ROCKET AF Steering Committee & Investigators

N1 - The ROCKET AF trial was sponsored by Johnson & Johnson Pharmaceutical Research & Development (Raritan, NJ) and Bayer HealthCare AG (Leverkusen, Germany).

PY - 2016

Y1 - 2016

KW - atrial fibrillation

KW - mortality

KW - rivaroxaban

KW - stroke

KW - warfarin

U2 - 10.1161/JAHA.115.002197)

DO - 10.1161/JAHA.115.002197)

M3 - Article

SN - 0098-7484

VL - 5

JO - JAMA

JF - JAMA

IS - 3

M1 - e002197

ER -